Yata Kenichiro, Abe Masahiro, Matsumoto Toshio
University of Tokushima Graduate School of Medicine, Department of Medicine and Bioregulatory Sciences.
Clin Calcium. 2008 Apr;18(4):438-46.
Myeloma cells stimulate bone resorption by enhancing osteoclast formation and suppress bone formation by inhibiting osteoblast differentiation. Macrophage inflammatory protein (MIP)-1alpha and MIP-1beta as well as RANK ligand play a major role in the enhancement of bone resorption in myeloma. Myeloma cell-derived soluble Wnt inhibitors as well as TGF-beta released from the bone tissues through enhanced bone resorption are thought to suppress osteoblast differentiation. Such pathognomonically skewed cellular components in the bone marrow create a microenvironment suitable for myeloma cell growth and survival (a myeloma niche) , which should be targeted to suppress myeloma expansion along with amelioration of bone lesions.
骨髓瘤细胞通过增强破骨细胞形成来刺激骨吸收,并通过抑制成骨细胞分化来抑制骨形成。巨噬细胞炎性蛋白(MIP)-1α和MIP-1β以及核因子κB受体活化因子配体在骨髓瘤骨吸收增强中起主要作用。骨髓瘤细胞衍生的可溶性Wnt抑制剂以及通过增强骨吸收从骨组织释放的转化生长因子-β被认为可抑制成骨细胞分化。骨髓中这种特征性倾斜的细胞成分创造了一个适合骨髓瘤细胞生长和存活的微环境(骨髓瘤龛),应针对此微环境来抑制骨髓瘤的扩展并改善骨病变。